NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

$1.74  +0.08 (4.82%)
As of 03/24/2023 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  
IPO date:  12/09/2021
Outstanding shares:  11,790,963
Average volume:  38,093
Market cap:   $19,572,999
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%